What are examples of P-gp substrates? A Comprehensive Guide

Over 480 drugs have been identified as P-glycoprotein (P-gp) substrates, with the number continually growing [1.8.5]. Understanding what are examples of P-gp substrates is crucial for predicting drug interactions and therapeutic outcomes, as P-gp can significantly alter a drug's absorption and distribution [1.5.6].

Quick Summary

P-glycoprotein (P-gp) is a transport protein that removes drugs from cells. Key P-gp substrates include digoxin, dabigatran, fexofenadine, and many cancer drugs, impacting their clinical effectiveness and interaction potential.

Key Points

• What P-gp Is: P-glycoprotein (P-gp) is a protein pump that removes drugs and toxins from cells, affecting drug absorption and distribution [1.4.1, 1.4.2].

• Substrate Definition: A P-gp substrate is any drug or compound that P-gp can bind to and transport out of a cell [1.9.4].

• Key Substrate Examples: Common P-gp substrates include digoxin, dabigatran, apixaban, fexofenadine, and numerous anticancer drugs like paclitaxel [1.3.1, 1.2.3].

• Clinical Significance: P-gp activity is a major cause of drug-drug interactions and multidrug resistance in cancer chemotherapy [1.5.5, 1.7.2].

• Inhibitors Increase Risk: P-gp inhibitors (e.g., verapamil, clarithromycin) block the pump, increasing substrate drug levels and the risk of toxicity [1.2.5, 1.4.3].

• Inducers Reduce Efficacy: P-gp inducers (e.g., rifampin, St. John's Wort) boost the pump's activity, lowering substrate drug levels and potentially causing treatment failure [1.2.5].

• Location Matters: P-gp is found in key barrier tissues like the intestine, blood-brain barrier, liver, and kidneys, where it controls drug access and removal [1.7.4].

Understanding P-glycoprotein (P-gp) and Its Function

P-glycoprotein (P-gp), also known as Multidrug Resistance Protein 1 (MDR1) or ABCB1, is a vital protein that acts as a cellular gatekeeper [1.4.3, 1.7.2]. It is an ATP-dependent efflux pump, meaning it uses energy to actively transport a wide variety of substances, known as substrates, out of cells [1.4.1, 1.7.4]. This function is a protective mechanism, preventing the accumulation of potentially harmful toxins and xenobiotics (foreign substances) in critical areas [1.4.2].

P-gp is strategically located in tissues that form barriers in the body [1.7.4]:

• Intestines: It limits the absorption of drugs from the gut into the bloodstream by pumping them back into the intestinal lumen [1.4.4, 1.4.5].
• Blood-Brain Barrier: It protects the brain by preventing substances from entering the central nervous system [1.4.6].
• Liver and Kidneys: It facilitates the excretion of drugs and metabolites into bile and urine [1.4.5].
• Placenta: It helps protect the developing fetus from exposure to certain drugs and toxins [1.4.6].

Because of this pumping action, P-gp plays a significant role in a drug's pharmacokinetics, influencing its absorption, distribution, metabolism, and excretion (ADME). The overexpression of P-gp is a major reason for multidrug resistance (MDR) in cancer cells, where it pumps chemotherapy agents out of tumor cells, reducing their effectiveness [1.7.2].

What Defines a P-gp Substrate?

A P-gp substrate is any compound that the P-gp pump can recognize and transport [1.9.4]. These are typically lipophilic (fat-soluble) and amphipathic molecules [1.7.4, 1.8.5]. The interaction between P-gp and its substrates is complex and clinically significant. When a patient takes multiple medications, the potential for drug-drug interactions (DDIs) involving P-gp is high. These interactions can occur when one drug alters the P-gp-mediated transport of another [1.5.4].

Comprehensive Examples of P-gp Substrates by Drug Class

P-gp transports a broad range of structurally diverse drugs. Below are examples categorized by their therapeutic class.

Cardiovascular Drugs

Many widely used cardiovascular drugs are P-gp substrates. Interactions here are critical because many of these medications have a narrow therapeutic index, meaning small changes in concentration can lead to toxicity or loss of efficacy [1.5.5].

• Anticoagulants: Dabigatran, Apixaban, Edoxaban, Rivaroxaban [1.3.1, 1.6.2]
• Antiarrhythmics: Digoxin, Quinidine, Amiodarone [1.2.3, 1.8.4]
• Calcium Channel Blockers: Verapamil, Diltiazem [1.8.5]
• Statins: Atorvastatin, Lovastatin, Simvastatin [1.8.3]
• Beta-Blockers: Carvedilol, Celiprolol [1.2.1, 1.9.4]

Anticancer Agents (Oncology)

P-gp is famously implicated in the failure of chemotherapy. Its ability to efflux cytotoxic drugs from cancer cells is a primary mechanism of multidrug resistance [1.7.4].

• Taxanes: Paclitaxel, Docetaxel [1.2.3, 1.7.4]
• Vinca Alkaloids: Vincristine, Vinblastine [1.2.3, 1.7.4]
• Anthracyclines: Doxorubicin, Daunorubicin [1.2.3, 1.7.4]
• Tyrosine Kinase Inhibitors (TKIs): Imatinib, Gefitinib, Sunitinib [1.7.2, 1.8.4]
• Topoisomerase Inhibitors: Etoposide, Teniposide [1.2.3, 1.7.4]

Immunosuppressants

These drugs require careful dose monitoring, and their levels are significantly affected by P-gp activity.

• Cyclosporine [1.3.1]
• Tacrolimus [1.3.1]
• Sirolimus [1.2.5]

Other Notable P-gp Substrates

• Antibiotics: Erythromycin, Clarithromycin [1.2.1, 1.2.5]
• HIV Protease Inhibitors: Ritonavir, Saquinavir, Indinavir [1.2.6, 1.4.1]
• Antihistamines: Fexofenadine, Desloratadine [1.7.4]
• Gastrointestinal Agents: Loperamide, Ondansetron, Cimetidine [1.2.5, 1.2.6]
• Opioids: Morphine [1.8.4]
• Corticosteroids: Dexamethasone, Aldosterone [1.2.3, 1.8.4]

P-gp Inhibitors vs. Inducers: The Clinical Impact

The activity of P-gp can be modified by other substances, which are classified as inhibitors or inducers. Understanding these is crucial for managing drug therapy [1.6.4].

• P-gp Inhibitors: These substances block the function of the P-gp pump. When an inhibitor is co-administered with a P-gp substrate, it prevents the substrate from being pumped out of the cell. This leads to increased intracellular concentration and higher absorption, which can increase the risk of toxicity [1.2.1, 1.9.4].
• P-gp Inducers: These substances increase the expression or activity of the P-gp pump. When an inducer is given with a P-gp substrate, more of the substrate is pumped out of cells. This leads to lower absorption and reduced drug levels, potentially causing treatment failure [1.2.1].

Category	Action on P-gp Substrate Levels	Examples
P-gp Inhibitors	Increase substrate concentration	Verapamil, Amiodarone, Clarithromycin, Ketoconazole, Ritonavir, Cyclosporine, Grapefruit Juice [1.2.5, 1.4.3]
P-gp Inducers	Decrease substrate concentration	Rifampin, St. John's Wort, Carbamazepine, Phenytoin [1.2.5]

For example, if a patient taking digoxin (a P-gp substrate) starts taking amiodarone (a P-gp inhibitor), the amiodarone will block the P-gp pumps responsible for clearing digoxin. This can cause digoxin levels to rise to toxic levels [1.5.3]. Conversely, if a patient on dabigatran (a substrate) starts taking rifampin (an inducer), dabigatran levels could drop, increasing the risk of stroke [1.2.5].

Conclusion

P-glycoprotein is a critical factor in pharmacology, influencing the efficacy and safety of a vast number of medications. Identifying a drug as a P-gp substrate is essential for healthcare providers to anticipate and manage potential drug-drug interactions. By understanding the interplay between P-gp substrates, inhibitors, and inducers, clinicians can optimize therapeutic regimens, minimize adverse effects, and overcome challenges like multidrug resistance in cancer. As research continues, the list of known substrates and the understanding of these complex interactions will expand, paving the way for more personalized and effective medicine.

---

For further reading, an excellent resource on the molecular mechanisms of P-gp is available from the National Center for Biotechnology Information: P-glycoprotein: new insights into structure, physiological function, and clinical implication [1.3.2]

Frequently Asked Questions

What happens when a P-gp substrate is taken with a P-gp inhibitor?

When a P-gp substrate is taken with a P-gp inhibitor, the inhibitor blocks the P-gp pump. This reduces the efflux of the substrate drug, leading to its increased absorption and higher concentration in the blood, which can cause toxicity [1.2.1, 1.9.4].

What happens if you take a P-gp substrate with a P-gp inducer?

Taking a P-gp substrate with an inducer (like St. John's Wort or rifampin) increases the number and activity of P-gp pumps. This enhances the efflux of the substrate drug, leading to lower blood concentrations and potentially making the medication ineffective [1.2.1, 1.2.5].

Is digoxin a P-gp substrate?

Yes, digoxin is a well-known P-gp substrate with a narrow therapeutic index, making it highly susceptible to clinically significant drug interactions with P-gp inhibitors and inducers [1.3.1, 1.5.3].

Why is P-gp important in cancer treatment?

P-gp is a major cause of multidrug resistance (MDR) in cancer. It pumps chemotherapeutic drugs (which are often P-gp substrates) out of cancer cells, reducing their intracellular concentration and making the treatment less effective [1.7.2, 1.7.4].

Are all statins P-gp substrates?

Not all, but many common statins, including atorvastatin, simvastatin, and lovastatin, are considered P-gp substrates and inhibitors. In contrast, pravastatin and fluvastatin show no significant interaction with P-gp [1.8.3].

Can food interact with P-gp substrates?

Yes, certain foods and drinks can act as P-gp inhibitors. The most notable example is grapefruit juice, which can inhibit P-gp and increase the concentration of co-administered P-gp substrates [1.2.5].

What is the difference between a P-gp substrate and a CYP3A4 substrate?

P-gp is a transporter protein that pumps drugs out of cells, while CYP3A4 is a metabolic enzyme that breaks drugs down. Many drugs are substrates for both, meaning they are both transported by P-gp and metabolized by CYP3A4, leading to complex drug-drug interactions [1.3.3].